BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

5:45 PM
 | 
Mar 11, 2010
 |  BC Extra  |  Clinical News

Figitumumab, Sutent miss in Phase IIIs

Pfizer Inc. (NYSE:PFE) announced it discontinued a Phase III trial of figitumumab to treat non-small cell lung cancer (NSCLC) and said that Sutent sunitinib missed the primary endpoint in two Phase III trials to treat breast cancer. Pfizer ended the open-label ADVIGO 1018 trial of figitumumab after a DSMC said the human mAb targeting insulin-like growth factor-1 (IGF-1)...

Read the full 283 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >